LivaNova (NASDAQ:LIVN) Price Target Lowered to $64.00 at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price target dropped by equities research analysts at Needham & Company LLC from $75.00 to $64.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 53.48% from the company’s current price.

A number of other research analysts have also recently commented on the stock. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird boosted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $67.33.

LivaNova Price Performance

NASDAQ:LIVN opened at $41.70 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a 50-day moving average of $47.78 and a 200-day moving average of $49.62. LivaNova has a 52 week low of $40.51 and a 52 week high of $64.47. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of 99.29 and a beta of 1.00.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after acquiring an additional 265,291 shares during the period. Point72 Asset Management L.P. lifted its position in LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares during the period. Capital Research Global Investors lifted its position in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after purchasing an additional 258,730 shares during the period. Geode Capital Management LLC boosted its stake in shares of LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of LivaNova by 8.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after buying an additional 107,693 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.